Voreloxin Hydrochloride

• CAT Number: I002288
• CAS Number: 175519-16-1
• Molecular Formula: C18H20ClN5O4S
• Molecular Weight: 437.90
• Purity: ≥95%
• Synonyms: 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid;hydrochloride
• Target: Topoisomerase
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C18H19N5O4S.ClH/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18;/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26);1H/t12-,13-;/m0./s1
• InChIKey: JJZCCQHWCOXGCL-QNTKWALQSA-N
• SMILES: CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O.Cl

Voreloxin hydrochloride（Cat No.:I002288）is an antineoplastic agent that belongs to the class of drugs known as topoisomerase inhibitors. It specifically targets topoisomerase II, an enzyme critical for DNA replication and cell division, by stabilizing the enzyme-DNA complex, leading to DNA damage and subsequent cancer cell apoptosis. Voreloxin has been primarily studied for its effectiveness in treating acute myeloid leukemia (AML) and other hematological malignancies. Its mechanism of action and favorable pharmacokinetic profile make it a promising candidate for combination therapies, enhancing the effectiveness of existing chemotherapy regimens.

Reference

[1]. Hoch U, Lynch J, Sato Y et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65.
[2]. Hawtin RE, Stockett DE, Byl JA et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010 Apr 15;5(4):e10186.
[3]. Lancet JE, Ravandi F, Ricklis RM et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec;25(12):1808-14.
[4]. Krug LM, Crawford J, Ettinger DS et al. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol. 2011 Feb;6(2):384-6.
[5]. Advani RH, Hurwitz HI, Gordon MS et al. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res. 2010 Apr 1;16(7):2167-75.
[6]. Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)